Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors
Dirk Strumberg(Universitätsklinik Marien Hospital Herne), Brian Schwartz(Cyclacel Pharmaceuticals (United Kingdom)), Hal W. Hirte(Juravinski Cancer Centre), Heike Richly(Universitätsklinik Marien Hospital Herne), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Joseph P. Eder(Yale Cancer Center), Alain Hendlisz(London Cancer), Malcolm J. Moore(University Health Network), Jeffrey W. Clark(Massachusetts General Hospital), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell)
Cited by 418
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k